- Home
- MTZ vs INSM Comparison
MTZ vs INSM Comparison
Compare MTZ & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTZ
- INSM
- Stock Information
- Founded
- MTZ 1929
- INSM 1988
- Country
- MTZ United States
- INSM United States
- Employees
- MTZ N/A
- INSM N/A
- Industry
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- MTZ Industrials
- INSM Health Care
- Exchange
- MTZ Nasdaq
- INSM Nasdaq
- Market Cap
- MTZ 10.7B
- INSM 12.5B
- IPO Year
- MTZ N/A
- INSM 2000
- Fundamental
- Price
- MTZ $142.09
- INSM $73.81
- Analyst Decision
- MTZ Strong Buy
- INSM Strong Buy
- Analyst Count
- MTZ 14
- INSM 16
- Target Price
- MTZ $146.57
- INSM $83.64
- AVG Volume (30 Days)
- MTZ 963.1K
- INSM 1.6M
- Earning Date
- MTZ 10-31-2024
- INSM 10-31-2024
- Dividend Yield
- MTZ N/A
- INSM N/A
- EPS Growth
- MTZ N/A
- INSM N/A
- EPS
- MTZ 1.13
- INSM N/A
- Revenue
- MTZ $12,180,445,000.00
- INSM $342,958,000.00
- Revenue This Year
- MTZ $2.92
- INSM $18.96
- Revenue Next Year
- MTZ $8.94
- INSM $41.96
- P/E Ratio
- MTZ $125.97
- INSM N/A
- Revenue Growth
- MTZ 3.89
- INSM 22.13
- 52 Week Low
- MTZ $54.06
- INSM $21.92
- 52 Week High
- MTZ $147.23
- INSM $80.53
- Technical
- Relative Strength Index (RSI)
- MTZ 63.60
- INSM 55.36
- Support Level
- MTZ $134.63
- INSM $64.86
- Resistance Level
- MTZ $147.23
- INSM $74.32
- Average True Range (ATR)
- MTZ 4.60
- INSM 3.09
- MACD
- MTZ 0.05
- INSM 0.39
- Stochastic Oscillator
- MTZ 68.49
- INSM 94.61
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include the engineering, building, installation, maintenance, and upgrade of communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five reportable segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.